アダリムマブ、インフリキシマブ、エタネルセプトバイオシミラーの世界市場レポート 2025年

アダリムマブ、インフリキシマブ、エタネルセプトバイオシミラー市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.5％で74億4,000万米ドルに成長します。予測期間の成長は、ヘルスケア支出の増加、高齢化、医療アクセスの増加が市場成長の原動力になると考えられます。予測期間における主な動向としては、新製品の上市への注力、M&Aへの注力、戦略的パートナーシップの確立への注力、投資の拡大への注力などが挙げられます。

アダリムマブ、インフリキシマブ、エタネルセプトのバイオシミラーの市場参入は、ブランド薬の特許切れによって促進されます。特に、先発薬レミケードの特許切れ後にFDAがホスピーラのInflectraを承認したことで、米国では関節リウマチ、成人潰瘍性大腸炎、尋常性乾癬など様々な自己免疫疾患の治療が可能になった。同様にEUでは、アムジェン社のエンブレルの特許切れにより、エンブレルのバイオシミラーであるベネパリが欧州委員会から承認されました。ヒュミラの特許失効後、FDAによるヒュミラの6番目のバイオシミラーであるヒュリオの最近の承認（2020年7月）を含め、複数のバイオシミラーが市場に出回っています。その結果、ヒュミラ、エンブレル、レミケードなどのブランド生物学的製剤の特許切れは、アダリムマブ、インフリキシマブ、エタネルセプトのバイオシミラー市場の需要を促進すると予想されます。

自己免疫疾患の有病率の増加は、アダリムマブ、インフリキシマブ、エタネルセプトのバイオシミラー市場の成長を促進すると予想されます。自己免疫疾患は、免疫系の機能不全によって免疫細胞が体内の健康な細胞を攻撃することで発症します。アダリムマブ、インフリキシマブ、エタネルセプトは、腫瘍壊死因子（TNF）α阻害作用を持つ生物学的製剤として、さまざまな自己免疫疾患の治療に用いられています。2023年のジョンズ・ホプキンス大学によると、米国では人口の3％を占める約1,000万人が多様な自己免疫疾患に罹患しています。その結果、自己免疫疾患の急増がアダリムマブ、インフリキシマブ、エタネルセプトのバイオシミラー市場の成長促進に大きく寄与しています。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場：金利、インフレ、地政学、コロナ禍、回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界アダリムマブ、インフリキシマブ、エタネルセプトバイオシミラーPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界のアダリムマブ、インフリキシマブ、エタネルセプトバイオシミラー市場：成長率分析
• 世界のアダリムマブ、インフリキシマブ、エタネルセプトバイオシミラー市場の実績：規模と成長, 2019-2024
• 世界のアダリムマブ、インフリキシマブ、エタネルセプトバイオシミラー市場の予測：規模と成長, 2024-2029, 2034F
• 世界アダリムマブ、インフリキシマブ、エタネルセプトバイオシミラー総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界のアダリムマブ、インフリキシマブ、エタネルセプトバイオシミラー市場：製品別、実績と予測, 2019-2024, 2024-2029F, 2034F
• アダリムマブバイオシミラー
• インフリキシマブバイオシミラー
• シプレマブ
• 世界のアダリムマブ、インフリキシマブ、エタネルセプトバイオシミラー市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 病院薬局
• 小売薬局
• オンライン薬局
• 世界のアダリムマブ、インフリキシマブ、エタネルセプトバイオシミラー市場：用途別、実績と予測, 2019-2024, 2024-2029F, 2034F
• クローン病
• 乾癬性関節炎
• 関節リウマチ
• 潰瘍性大腸炎
• 強直性脊椎炎
• 尋常性乾癬
• その他の用途
• 世界のアダリムマブ、インフリキシマブ、エタネルセプトバイオシミラー市場アダリムマブバイオシミラーの種類別のサブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
• アムジェビタ（アムジェン）
• ヒュリモズ（サンドス）
• シルテゾ（ベーリンガーインゲルハイム）
• その他
• 世界のアダリムマブ、インフリキシマブ、エタネルセプトバイオシミラー市場インフリキシマブバイオシミラーのサブセグメンテーション（タイプ別）、実績と予測, 2019-2024, 2024-2029F, 2034F
• インフレクトラ（ファイザー）
• レムシマ（セルトリオン）
• イクシフィ（ファイザー）
• その他
• 世界のアダリムマブ、インフリキシマブ、エタネルセプトバイオシミラー市場シプレマブのサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
• シプレマブバイオシミラー
• 開発中のその他のバイオシミラー

第7章 地域別・国別分析

• 世界のアダリムマブ、インフリキシマブ、エタネルセプトバイオシミラー市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
• 世界のアダリムマブ、インフリキシマブ、エタネルセプトバイオシミラー市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• アダリムマブ、インフリキシマブ、エタネルセプトバイオシミラー市場：競合情勢
• アダリムマブ、インフリキシマブ、エタネルセプトバイオシミラー市場：企業プロファイル
  • Biogen Overview, Products and Services, Strategy and Financial Analysis
  • Novartis（Sandoz）Overview, Products and Services, Strategy and Financial Analysis
  • Pfizer Overview, Products and Services, Strategy and Financial Analysis
  • Amgen Overview, Products and Services, Strategy and Financial Analysis
  • Celltrion Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Samsung Bioepis（Samsung Biologics）
• Hetero Drugs Limited
• Fresenius Kabi AG
• Boehringer Ingelheim
• Biocon
• Zydus Lifesciences Limited
• Reliance Life Sciences
• Torrent Pharmaceuticals Ltd
• Sun Pharmaceutical Industries Ltd
• Cipla Limited
• Zhejiang Hisun Pharmaceutical Co. Ltd
• Bio-Thera Solutions, Ltd
• Innovent Biologics（Suzhou）Co. Ltd
• Janssen Biologics BV
• Shanghai CP Guojian Pharmaceutical Co. Ltd

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• アダリムマブ、インフリキシマブ、エタネルセプトバイオシミラー市場2029：新たな機会を提供する国
• アダリムマブ、インフリキシマブ、エタネルセプトバイオシミラー市場2029：新たな機会を提供するセグメント
• アダリムマブ、インフリキシマブ、エタネルセプトバイオシミラー市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Adalimumab, infliximab, and etanercept biosimilars represent an innovative class of medications designed to inhibit the effects of the inflammatory mediator tumor necrosis factor-alpha (TNF-alpha). Infliximab biosimilars, in particular, are chimeric monoclonal antibodies targeting TNF-alpha and are utilized in the treatment of immune system disorders.

These medications include various products such as adalimumab, infliximab, cipleumab, and etanercept. Adalimumab, classified as a biological drug, operates on the immune system to mitigate inflammation. Its diverse applications encompass treating conditions such as Crohn's disease, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, ankylosing spondylitis, plaque psoriasis, and others. These products are made available through different distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The adalimumab, infliximab, and etanercept biosimilars market research report is one of a series of new reports from The Business Research Company that provides adalimumab, infliximab, and etanercept biosimilars market statistics, including adalimumab, infliximab, and etanercept biosimilars industry global market size, regional shares, competitors with adalimumab, infliximab, and etanercept biosimilars market. This adalimumab, infliximab, and etanercept biosimilars market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The adalimumab, infliximab and etanercept biosimilars market size has grown rapidly in recent years. It will grow from $4.37 billion in 2024 to $4.98 billion in 2025 at a compound annual growth rate (CAGR) of 14.1%. The growth in the historic period can be attributed to increased healthcare expenditure, regulatory changes, regulatory changes, government initiatives and rising healthcare costs.

The adalimumab, infliximab and etanercept biosimilars market size is expected to see rapid growth in the next few years. It will grow to $7.44 billion in 2029 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to a rise in healthcare expenditure, an aging population and an increase in healthcare access will drive market growth. Major trends in the forecast period include focus on launching new products, focus on mergers and acquisitions, focus on establishing strategic partnerships, and focus on increasing investments.

The entrance of biosimilars into the market for adalimumab, infliximab, and etanercept is facilitated by the patent expiration of branded drugs. Notably, the FDA approved Hospira's Inflectra post the patent expiry of the branded drug Remicade, enabling treatment for various autoimmune diseases such as rheumatoid arthritis, adult ulcerative colitis, and plaque psoriasis in the United States. Similarly, in the EU, Amgen's Enbrel patent expiration led to the approval of Benepali, a biosimilar of Enbrel, by the European Commission. Following the expiry of Humira's patent, multiple biosimilars have become available in the market, including the recent approval (July 2020) of Hulio, the sixth biosimilar of Humira by the FDA. Consequently, the patent expiry of branded biologic drugs such as Humira, Enbrel, and Remicade is expected to propel demand in the adalimumab, infliximab, and etanercept biosimilars market.

The escalating prevalence of autoimmune diseases is anticipated to drive growth in the market for adalimumab, infliximab, and etanercept biosimilars. Autoimmune diseases arise from immune system dysfunction, leading immune cells to attack the body's healthy cells. Adalimumab, infliximab, and etanercept, as biological drugs with tumor necrosis factor (TNF) alpha inhibitors, are employed in treating various autoimmune diseases. According to Johns Hopkins University in 2023, approximately 10 million individuals in the US, constituting 3% of the population, are affected by diverse autoimmune illnesses. Consequently, the surge in autoimmune diseases' prevalence significantly contributes to driving the growth of the adalimumab, infliximab, and etanercept biosimilars market.

The brand-name versions of biosimilar drugs are expensive, and many are now being replaced by biosimilar versions following the expiration of their patents. The costs of branded biological drugs have nearly doubled in recent years. For example, in September 2022, the biologic medication Humira, used to treat autoimmune conditions such as rheumatoid arthritis and Crohn's disease, was priced at over $6,000 for a carton containing two pens without insurance. The transition to lower-cost biosimilar drugs is primarily due to the absence of clinically significant differences in safety and efficacy between the biosimilars and the original biologics. After the patent on the original adalimumab product, Humira, expired, the Danish healthcare system nearly completely transitioned to adalimumab biosimilars, resulting in an 82% reduction in medication costs.

Major companies in the adalimumab, infliximab, and etanercept biosimilars market are prioritizing the development of innovative products, such as citrate-free adalimumab, to offer enhanced services to consumers. Citrate-free adalimumab represents a formulation of the biological medication adalimumab devoid of citrate. For instance, in December 2022, Fresenius Kabi, a German-based manufacturer specializing in medicines and technologies for infusion, transfusion, and clinical nutrition, announced FDA approval for the biosimilar Idacio (adalimumab). This biosimilar is sanctioned for use in managing chronic autoimmune disorders across all permissible uses of the reference product. It has been meticulously crafted employing advanced analytical methodologies, intended for the treatment of various chronic conditions.

In February 2022, the Indian biopharmaceutical company Biocon Limited successfully acquired the biosimilar assets of Viatris, Inc., a U.S.-based biopharmaceutical and healthcare company, for a total of $3.34 billion. This strategic acquisition positions Biocon as a unique and vertically integrated global leader in biosimilars, providing an impetus for the expedited commercialization of its existing and future biosimilar portfolio on a global scale. The move is set to significantly enhance Biocon's product reach across international markets. Viatris, Inc. is recognized for its expertise in the development and specialization of biological and therapeutic agents.

Major companies operating in the adalimumab, infliximab and etanercept biosimilars market include Biogen, Novartis (Sandoz), Pfizer, Amgen, Celltrion, Samsung Bioepis (Samsung Biologics), Hetero Drugs Limited, Fresenius Kabi AG, Boehringer Ingelheim, Biocon, Zydus Lifesciences Limited, Reliance Life Sciences, Torrent Pharmaceuticals Ltd, Sun Pharmaceutical Industries Ltd, Cipla Limited, Zhejiang Hisun Pharmaceutical Co. Ltd, Bio-Thera Solutions, Ltd, Innovent Biologics (Suzhou) Co. Ltd, Janssen Biologics BV, Shanghai CP Guojian Pharmaceutical Co. Ltd, Sansheng Guojian, Shanghai Junshi Biosciences Co. Ltd, Mabwell Bioscience Co. Ltd, LG Chem, Nippon Kayaku, Mochida Pharmaceutical Co. Ltd, mAbxience, Allergan, Microgen, Geropharm, Valenta, NovaMedica Veropharm, Biocad, Roche, Bristol-Myers Squibb, Celon Pharma, SynBio, Ache, Eurofarma, Teva Pharmaceuticals, Oramed Pharmaceuticals, Entera Bio, Julphar, Hikma Pharmaceuticals, Mylan, BIOPHARMA-MEA, NeoTX, AID Genomics Limited, Altis Biologics, Next Biosciences, Viome, Inqaba Biotechnical Industries (Pty) Ltd

North America was the largest region in the adalimumab, infliximab, and etanercept biosimilars market in 2024. The regions covered in the adalimumab, infliximab, and etanercept biosimilars market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

The countries covered in the adalimumab, infliximab and etanercept biosimilars market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Canada, Spain

The adalimumab, infliximab, and etanercept biosimilars market consists of sales of Amgevita, Hyrimoz, and Idacio. Values in this market are ""factory gate values,"" that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adalimumab, Infliximab and Etanercept Biosimilars Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adalimumab, infliximab and etanercept biosimilars market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adalimumab, infliximab and etanercept biosimilars ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The adalimumab, infliximab and etanercept biosimilars market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product: Adalimumab Biosimilars, Infliximab Biosimilars, Cipleumab
• 2) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies
• 3) By Application: Crohn's Disease, Psoriatic Arthritis, Rheumatoid Arthritis, Ulcerative Colitis, Ankylosing Spondylitis, Plaque Psoriasis, Other Applications
• Subsegments:
• 1) By Adalimumab Biosimilars: Amjevita (Amgen); Hyrimoz (Sandoz); Cyltezo (Boehringer Ingelheim); Others
• 2) By Infliximab Biosimilars: Inflectra (Pfizer); Remsima (Celltrion); Ixifi (Pfizer); Others
• 3) By Cipleumab: Cipleumab Biosimilars; Other Biosimilars in Development
• Companies Mentioned: Biogen; Novartis (Sandoz); Pfizer; Amgen; Celltrion
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Adalimumab, Infliximab and Etanercept Biosimilars Market Characteristics

3. Adalimumab, Infliximab and Etanercept Biosimilars Market Trends And Strategies

4. Adalimumab, Infliximab and Etanercept Biosimilars Market - Macro Economic Scenario including the impact of Interest Rates, Inflation, Geopolitics and Covid And Recovery on the Market

5. Global Adalimumab, Infliximab and Etanercept Biosimilars Growth Analysis And Strategic Analysis Framework

• 5.1. Global Adalimumab, Infliximab and Etanercept Biosimilars PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Growth Rate Analysis
• 5.4. Global Adalimumab, Infliximab and Etanercept Biosimilars Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Adalimumab, Infliximab and Etanercept Biosimilars Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Adalimumab, Infliximab and Etanercept Biosimilars Total Addressable Market (TAM)

6. Adalimumab, Infliximab and Etanercept Biosimilars Market Segmentation

• 6.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Adalimumab Biosimilars
• Infliximab Biosimilars
• Cipleumab
• 6.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies
• 6.3. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Crohn's Disease
• Psoriatic Arthritis
• Rheumatoid Arthritis
• Ulcerative Colitis
• Ankylosing Spondylitis
• Plaque Psoriasis
• Other Applications
• 6.4. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Sub-Segmentation Of Adalimumab Biosimilars, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Amjevita (Amgen)
• Hyrimoz (Sandoz)
• Cyltezo (Boehringer Ingelheim)
• Others
• 6.5. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Sub-Segmentation Of Infliximab Biosimilars, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inflectra (Pfizer)
• Remsima (Celltrion)
• Ixifi (Pfizer)
• Others
• 6.6. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Sub-Segmentation Of Cipleumab, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cipleumab Biosimilars
• Other Biosimilars in Development

7. Adalimumab, Infliximab and Etanercept Biosimilars Market Regional And Country Analysis

• 7.1. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Adalimumab, Infliximab and Etanercept Biosimilars Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market

• 8.1. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Adalimumab, Infliximab and Etanercept Biosimilars Market

• 9.1. China Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
• 9.2. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Adalimumab, Infliximab and Etanercept Biosimilars Market

• 10.1. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market

• 11.1. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
• 11.2. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market

• 12.1. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market

• 13.1. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market

• 14.1. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
• 14.2. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market

• 15.1. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
• 15.2. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Adalimumab, Infliximab and Etanercept Biosimilars Market

• 16.1. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market

• 17.1. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Adalimumab, Infliximab and Etanercept Biosimilars Market

• 18.1. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Adalimumab, Infliximab and Etanercept Biosimilars Market

• 19.1. Italy Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Adalimumab, Infliximab and Etanercept Biosimilars Market

• 20.1. Spain Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market

• 21.1. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
• 21.2. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market

• 22.1. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Adalimumab, Infliximab and Etanercept Biosimilars Market

• 23.1. North America Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
• 23.2. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Adalimumab, Infliximab and Etanercept Biosimilars Market

• 24.1. USA Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
• 24.2. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Adalimumab, Infliximab and Etanercept Biosimilars Market

• 25.1. Canada Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
• 25.2. Canada Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Adalimumab, Infliximab and Etanercept Biosimilars Market

• 26.1. South America Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
• 26.2. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market

• 27.1. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market

• 28.1. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
• 28.2. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market

• 29.1. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market Overview
• 29.2. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Adalimumab, Infliximab and Etanercept Biosimilars Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Landscape And Company Profiles

• 30.1. Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Landscape
• 30.2. Adalimumab, Infliximab and Etanercept Biosimilars Market Company Profiles
  • 30.2.1. Biogen Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Novartis (Sandoz) Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Pfizer Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Amgen Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Celltrion Overview, Products and Services, Strategy and Financial Analysis

31. Adalimumab, Infliximab and Etanercept Biosimilars Market Other Major And Innovative Companies

• 31.1. Samsung Bioepis (Samsung Biologics)
• 31.2. Hetero Drugs Limited
• 31.3. Fresenius Kabi AG
• 31.4. Boehringer Ingelheim
• 31.5. Biocon
• 31.6. Zydus Lifesciences Limited
• 31.7. Reliance Life Sciences
• 31.8. Torrent Pharmaceuticals Ltd
• 31.9. Sun Pharmaceutical Industries Ltd
• 31.10. Cipla Limited
• 31.11. Zhejiang Hisun Pharmaceutical Co. Ltd
• 31.12. Bio-Thera Solutions, Ltd
• 31.13. Innovent Biologics (Suzhou) Co. Ltd
• 31.14. Janssen Biologics BV
• 31.15. Shanghai CP Guojian Pharmaceutical Co. Ltd

32. Global Adalimumab, Infliximab and Etanercept Biosimilars Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Adalimumab, Infliximab and Etanercept Biosimilars Market

34. Recent Developments In The Adalimumab, Infliximab and Etanercept Biosimilars Market

35. Adalimumab, Infliximab and Etanercept Biosimilars Market High Potential Countries, Segments and Strategies

• 35.1 Adalimumab, Infliximab and Etanercept Biosimilars Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Adalimumab, Infliximab and Etanercept Biosimilars Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Adalimumab, Infliximab and Etanercept Biosimilars Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer